Genomic markers for prediction of long-term response to 2 years of growth hormone (GH) therapy
US9206480B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 2012 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Aug 20, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.